April 2, 2022- ARTICLE
Lansky A, White J, Stewart J, et al. CLINICAL PREDICTORS OF EMBOLIC BURDEN AFTER TAVR: AN ANALYSIS OF THE SAFEPASS 2 CLINICAL STUDY. J Am Coll Cardiol. 2022 Mar, 79 (9_Supplement) 628. https://doi.org/10.1016/S0735-1097(22)01619-9
May 25, 2021- PRESS RELEASE
Emboline Raises over $55 Million in Series D Funding for Pivotal FDA Clinical Study and Market Launch of the Emboliner® Embolic Protection Catheter to Minimize Stroke Risk from TAVR
January 5, 2021- PRESS RELEASE
October 14, 2020- ABSTRACT
October 14, 2020- ABSTRACT
January 15, 2020- PRESS RELEASE
Emboline Completes Enrollment in SafePass 2 Clinical Study of Emboliner Embolic Protection Catheter
June 5, 2018- PRESS RELEASE
Emboline, Inc. Completes Initial Human Clinical Cases with the Emboliner Embolic Protection Catheter
April 19, 2018- PRESS RELEASE
Emboline, Inc. Completes Funding of Over $10 million
October 28, 2016- PRESS RELEASE
September 15, 2014- PRESENTATION
December 2, 2013- PRESENTATION
Emboline, Inc.
Santa Cruz, CA USA
Tel: +1 (831) 900-5020 • Fax: +1 (831) 900-5019
info@emboline.com